drugset / Trial / NCT02264418

Safety and Tolerability of ODM-203 in Subjects With Advanced Solid Tumours

NCT02264418 ↗

Phase 1 Completed 84 enrolled Orion Corporation, Orion Pharma
Non-randomizedSingle-groupOpen-labelOther

Summary

The purpose of this first-in-human study is to evaluate the safety and tolerability of escalating doses of ODM-203 in subjects with advanced solid tumours and to determine the maximum tolerated dose and dose limiting toxicities.

Timeline

Start
2014-09-18
Primary completion
2019-05
Completion
2019-05

Drugs

EvaluationDrugModalityDoseRoute
Subject ODM-203 Unknown 400 mg Oral

Indications